FDA issues EUA for monoclonal antibody for treatment of hospitalized COVID-19 patients
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) to Genentech, a member of the Roche Group, for tocilizumab (Actemra) for the treatment of hospitalized adults and pediatric patients. Read More
New in vitro models offer effective way to study respiratory viruses
A new accessible and scalable protocol for manufacturing in vitro lung cell models could have applications in the development of new therapies for respiratory viral infections and drug toxicology studies on human lungs. Details about the protocol were published in Stem Cells on June 21. Read More
Enochian gets license for inhaled treatment tech
Enochian BioSciences has acquired a license for technology that can potentially treat and prevent all variants of the coronavirus as well as influenza. Read More
New AI model could predict viral jumps from animals to humans
A new artificial intelligence (AI)-based computational model called SweetNet aimed at characterizing complex carbohydrates could help predict which viruses are likely to spread from animals to humans. The details of the research were published in Cell Reports on June 15. Read More
Novavax touts COVID-19 vaccine results
Novavax is highlighting study results that demonstrate the efficacy of its COVID-19 vaccine, NVX-CoV2373, as well as a new COVID-19 vaccine it is developing for variants of the disease. Read More
Moderna files U.S. EUA for COVID-19 vaccine in adolescents
Moderna announced it has requested an emergency use authorization (EUA) from the U.S. Food and Drug Administration for its COVID-19 vaccine in adolescents. Read More
U.S. to donate 500M doses of Pfizer-BioNTech COVID-19 vaccines
The U.S. government is buying 500 million doses of the Pfizer-BioNTech COVID-19 vaccine to distribute to low- and lower middle-income countries and organizations that support them, according to a release from the companies. Read More
Scientists show how SARS-CoV-2 wreaks havoc in lungs
Scientists at the U.S. Department of Energy's Brookhaven National Laboratory have published the first detailed atomic-level model of the SARS-CoV-2 envelope protein in a study published June 8 in Nature Communications. The model shows how the virus interacts with lung proteins, helping to explain how SARS-CoV-2 causes extensive lung damage. Read More
Moderna, Medison partner on Moderna's COVID-19 vaccine
Moderna and Medison Pharma announced that they are entering into a marketing agreement for Moderna's COVID-19 vaccine across central Europe and Israel. Read More
COVID-19 therapies could come from existing drugs
At least four drugs that have already been approved by the U.S. Food and Drug Administration may be effective as COVID-19 therapies, according to a study published on June 3 in Nature Communications by researchers from the Scripps Research Institute in La Jolla, CA. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter